Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCND2 | P30279 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | BRD2 | P25440 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955552 | 0.89 | CDK4 (0.41) | CDK4CCND1CCND2CCND3EGLN1 | |
| SCHEMBL2952262 | 0.85 | ALDH1A1 (0.52) | MAPTGAAALDH1A1TDP1KDM4E | |
| Ammonia Solution, Strong SCHEMBL2958678 | 0.83 | CDK4 (0.41) | CDK4CCND1CCND2CCND3MAPT | |
| Ammonia Solution, Strong SCHEMBL1267334 | 0.81 | CDK4 (0.38) | CDK4CCND1CCND2CCND3MAPT | |
| SCHEMBL2949022 | 0.73 | CDK4 (0.40) | CDK4CCND1CCND2CCND3MAPT | |
| SCHEMBL2957695 | 0.71 | CXCR2 (0.40) | CDK4CCND1CCND2CCND3MAPT | |
| SCHEMBL2958436 | 0.70 | KMT2A (0.41) | CDK4CCND1CCND2CCND3MAPT | |
| SCHEMBL2958575 | 0.70 | CDK4 (0.38) | CDK4CCND1CCND2CCND3MAPT | |
| SCHEMBL2952675 | 0.70 | KMT2A (0.41) | CDK4CCND1CCND2CCND3ALDH1A1 | |
| SCHEMBL27617043 | 0.70 | FEN1 (0.41) | ALDH1A1KMT2AFEN1PKML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569953-B1 | PEPTIDE GAP JUNCTION MODULATORS | ZEALAND PHARMA AS (DK) | 2010-09-29 | — | — | EP | disclosed |
| US-7763729-B2 | Bicyclic heteroaromatic derivatives | UCB PHARMA S.A. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | CELLTECH R&D LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
| US-7423047-B2 | Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2008-09-09 | — | — | US | disclosed |
| US-20060194947-A1 | Peptide gap junction modulators | ZEALAND PHARMA A/S (DK) | 2006-08-31 | — | — | US | disclosed |
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | UCB PHARMA S.A. (BE) | 2006-01-05 | — | — | US | disclosed |
| EP-1569953-A1 | PEPTIDE GAP JUNCTION MODULATORS | Zealand Pharma A/S (DK) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004048400-A1 | PEPTIDE GAP JUNCTION MODULATORS | ZEALAND PHARMA A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004025-A1 | Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors | MAPK1, CNKSR1, ALK | CDK4 743/4885CCND1 655/4885CCND2 932/4885 |
| US-20090042877-A1 | Bicyclic Heteroaromatic Derivatives | MAPK1, CNKSR1, CBR1 | CDK4 689/4885CCND1 533/4885CCND2 932/4885 |
| US-20060194947-A1 | Peptide gap junction modulators | GJA1, GJB2, GAP43 | CDK4 4052/4885CCND1 4549/4885CCND2 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.